Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

2,604 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Quality of life improvements among cancer patients in remission following the consumption of Agaricus blazei Murill mushroom extract.
Ohno S, Sumiyoshi Y, Hashine K, Shirato A, Kyo S, Inoue M. Ohno S, et al. Complement Ther Med. 2013 Oct;21(5):460-7. doi: 10.1016/j.ctim.2013.07.001. Epub 2013 Aug 12. Complement Ther Med. 2013. PMID: 24050580
Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission.
Ohno S, Sumiyoshi Y, Hashine K, Shirato A, Kyo S, Inoue M. Ohno S, et al. Evid Based Complement Alternat Med. 2011;2011:192381. doi: 10.1155/2011/192381. Epub 2011 Apr 18. Evid Based Complement Alternat Med. 2011. PMID: 21584278 Free PMC article.
Phase I trial of Wilms' Tumor 1 (WT1) peptide vaccine with GM-CSF or CpG in patients with solid malignancy.
Ohno S, Okuyama R, Aruga A, Sugiyama H, Yamamoto M. Ohno S, et al. Anticancer Res. 2012 Jun;32(6):2263-9. Anticancer Res. 2012. PMID: 22641661 Clinical Trial.
Complementary and alternative medicine in Japan.
Suzuki N, Ohno S, Kamei T, Yoshiki Y, Kikuchi Y, Okubo K, Ohta T, Shimizu S, Koshimura S, Taru A, Inoue M. Suzuki N, et al. Among authors: ohno s. Adv Exp Med Biol. 2004;546:9-25. doi: 10.1007/978-1-4757-4820-8_3. Adv Exp Med Biol. 2004. PMID: 15584364 No abstract available.
Immunohistochemical detection of WT1 protein in endometrial cancer.
Ohno S, Dohi S, Ohno Y, Kyo S, Sugiyama H, Suzuki N, Inoue M. Ohno S, et al. Among authors: ohno y. Anticancer Res. 2009 May;29(5):1691-5. Anticancer Res. 2009. PMID: 19443388
Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer.
Nakamura M, Kyo S, Zhang B, Zhang X, Mizumoto Y, Takakura M, Maida Y, Mori N, Hashimoto M, Ohno S, Inoue M. Nakamura M, et al. Among authors: ohno s. Hum Pathol. 2010 Nov;41(11):1516-29. doi: 10.1016/j.humpath.2010.05.006. Epub 2010 Aug 30. Hum Pathol. 2010. PMID: 20800872
CD133(+) cells had a greater S-phase fraction than CD133(-) cells, and the serum starvation that induced G0/G1 accumulation decreased the population of CD133(+) cells. ...
CD133(+) cells had a greater S-phase fraction than CD133(-) cells, and the serum starvation that induced G0/G1 accumulation decreased …
Frequency of myeloid dendritic cells can predict the efficacy of Wilms' tumor 1 peptide vaccination.
Ohno S, Takano F, Ohta Y, Kyo S, Myojo S, Dohi S, Sugiyama H, Ohta T, Inoue M. Ohno S, et al. Anticancer Res. 2011 Jul;31(7):2447-52. Anticancer Res. 2011. PMID: 21873158 Clinical Trial.
WT1 peptide vaccine stabilized intractable ovarian cancer patient for one year: a case report.
Dohi S, Ohno S, Ohno Y, Takakura M, Kyo S, Soma G, Sugiyama H, Inoue M. Dohi S, et al. Among authors: ohno s, ohno y. Anticancer Res. 2011 Jul;31(7):2441-5. Anticancer Res. 2011. PMID: 21873157
There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). ...
There was a weak positive correlation between CA125 and mononuclear phagocyte/lymphocyte ratio (Spearman's ϱ=0.275, p=0.015). ...
WT1 expression correlates with angiogenesis in endometrial cancer tissue.
Dohi S, Ohno S, Ohno Y, Kyo S, Soma G, Sugiyama H, Inoue M. Dohi S, et al. Among authors: ohno s, ohno y. Anticancer Res. 2010 Aug;30(8):3187-92. Anticancer Res. 2010. PMID: 20871039
Wilms' tumor 1 (WT1) peptide immunotherapy for gynecological malignancy.
Ohno S, Kyo S, Myojo S, Dohi S, Ishizaki J, Miyamoto K, Morita S, Sakamoto J, Enomoto T, Kimura T, Oka Y, Tsuboi A, Sugiyama H, Inoue M. Ohno S, et al. Anticancer Res. 2009 Nov;29(11):4779-84. Anticancer Res. 2009. PMID: 20032435 Clinical Trial.
2,604 results
Jump to page
Feedback